ArticleAnnals of translational medicine2021
A novel prognostic nomogram for patients with surgically resected perihilar cholangiocarcinoma: a SEER-based study.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Development and validation of a machine learning-based nomogram for survival prediction of patients with hilar cholangiocarcinoma after curative-intent resection.Scientific reports · 2025Article
- Multivariable prediction model for both 90-day mortality and long-term survival for individual patients with perihilar cholangiocarcinoma: does the predicted survival justify the surgical risk?The British journal of surgery · 2023Article
- Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study.Journal of gastrointestinal oncology · 2022Article
- Impact of Body Mass Index on Tumor Recurrence in Patients Undergoing Liver Resection for Perihilar Cholangiocarcinoma (pCCA).Cancers · 2021Article
- Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study.Annals of translational medicine · 2021Article
- Comparison of Four Lymph Node Stage Methods for Predicting the Prognosis of Distal Cholangiocarcinoma Patients After Surgery.Frontiers in oncology · 2021Article
- A Nomogram Based on the Log Odds of Positive Lymph Nodes Predicts the Prognosis of Patients With Distal Cholangiocarcinoma After Surgery.Frontiers in surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare the predictive efficacy of four different lymph node (LN) staging systems on the overall survival (OS) of patients with surgically resected perihilar cholangiocarcinoma (pCCA), and construct a novel prognostic nomogram to predict OS in pCCA patients.
methodsPatients with pCCA that underwent surgical resection between 2004 to 2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database (n=1,173). Patients were randomly divided into a modeling cohort and an internal verification cohort. To compare the prognostic efficacy of four different N staging systems [American Joint Committee on Cancer (AJCC) 7
resultsOf the four different N staging methods, LODDS was considered to be the most effective LN staging system for evaluating the prognosis of patients with surgically resected pCCA, according to the values calculated for C-index, AUC, and AIC. After validation by C-indexes and calibration curves, the constructed nomogram accurately predicted the OS of pCCA patients.
conclusionsFor patients with surgically resected pCCA, LODDS was found to be the most accurate N staging system. The novel LODDS-based nomogram constructed in this study provides an accurate method for predicting patient survival in pCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.